<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121100">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02013271</url>
  </required_header>
  <id_info>
    <org_study_id>CL0017-01</org_study_id>
    <nct_id>NCT02013271</nct_id>
  </id_info>
  <brief_title>Lutonix® DCB Versus Standard Balloon Angioplasty for Treatment of Long Lesions in Femoropopliteal Arteries</brief_title>
  <acronym>LL RCT</acronym>
  <official_title>A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Long Lesions in Femoropopliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>C. R. Bard</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>C. R. Bard</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of the Lutonix Drug Coated Balloon for treatment of long
      (≥ 14 cm) lesions in the femoropopliteal artery (SFA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety: Freedom from death, target limb amputation, and Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 Days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Primary Patency</measure>
    <time_frame>12 Months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Composite of freedom from all-cause perioperative (≤ 30 day) death and freedom from the following: target limb amputation, target limb re-intervention, and target-limb-related death.</measure>
    <time_frame>1, 6, 12, 24, 36 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The following endpoints will be assessed at 1, 6, 12, 24 and 36 months:
All-cause death
Amputation (above the ankle)-Free Survival (AFS)
Target Vessel Revascularization (TVR)
Reintervention for treatment of thrombosis of the target vessel or embolization to its distal vasculature
Major vascular complications
Readmission for cardiovascular events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Acute Device, Technical and Procedural success</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The following endpoints will be assessed at 6, 12 and 24 Months:
Primary and Secondary Patency
Target Lesion Revascularization (TLR)
Clinically-driven
Total (clinical and DUS/angiography-driven)
Change of Rutherford classification from baseline
Change of resting Ankle Brachial Index (ABI) from baseline
Change in Walking Impairment Questionnaire from baseline
Change in quality of life from baseline, as measured by EQ-5D</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Femoral Artery Occlusion</condition>
  <condition>Femoral Arterial Stenosis</condition>
  <arm_group>
    <arm_group_label>Lutonix DCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lutonix Paclitaxel Drug Coated Balloon</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTA Catheter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard Uncoated Balloon Angioplasty Catheter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lutonix Paclitaxel Drug Coated Balloon</intervention_name>
    <arm_group_label>Lutonix DCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard Uncoated Balloon Angioplasty Catheter</intervention_name>
    <description>PTA Catheter</description>
    <arm_group_label>PTA Catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Clinical Criteria

          1. ≥ 18 years of age;

          2. Rutherford Clinical Category 2-4;

          3. Subject is legally competent and voluntarily agrees to participation and the study's
             provisions;

          4. ≥ 70% stenosis of a native femoropopliteal artery;

          5. TASC II Class C or D Lesions with intended target lesion treatment segment(s)
             cumulatively ≥14 cm in length;

          6. de novo lesion(s) or non-stented restenotic lesion(s) &gt; 90 days from prior
             angioplasty procedure;

          7. Target vessel diameter between ≥ 4 and ≤ 7 mm;

          8. Successful wire crossing of lesion and predilatation;

          9. No other prior vascular interventions (including contralateral limb) within 2 weeks
             before and/or planned 30 days after the protocol treatment.

        Exclusion Criteria:

          1. Patient is contraindicated to use Lutonix Drug Coated Balloon per the current
             Instructions For Use (IFU);

          2. Life expectancy of &lt; 1year;

          3. Patient is currently participating in an investigational drug or other device study
             or previously enrolled in this study;

          4. History of stroke within 3 months;

          5. History of myocardial infarction, thrombolysis or angina within 2 weeks of
             enrollment;

          6. Prior vascular surgery of index limb with exception of remote common femoral patch
             angioplasty;

          7. Target lesion involves a previously placed stent;

          8. Inability to take required study medications or allergy to contrast that cannot be
             adequately managed with pre- and post-procedure medication;

          9. Significant inflow disease;

         10. Known inadequate distal outflow or planned future treatment of vascular disease;

         11. Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in
             target vessel;

         12. Use of adjunctive treatment modalities (e.g. laser, atherectomy or cryoplasty)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Banyai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital Lucerne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prof. Eric Ducasse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Erickson</last_name>
    <email>NHP-Lutonix-LLRCT@crbard.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Clinical Center Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Britta Vogel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Niels Zorger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medinos Kliniken Sonneberg</name>
      <address>
        <city>Sonneberg</city>
        <zip>96515</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marcus Thieme, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 27, 2014</lastchanged_date>
  <firstreceived_date>December 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
